This article is a correction to:
The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
CORRECTION article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1536374
Corrigendum: The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
Provisionally accepted
Chaokun Wang 1* Shuzhen Deng 2* Jing Chen 1* Xiangyun Xu 1* Xiaochen Hu 1* Dejiu Kong 1*
Gaofeng Liang 2
Xiang Yuan 1 Yuanpei Li 3*
Xinshuai Wang 1*- 1 Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan Province, China
- 2 Medical College, Henan University of Science and Technology, Luoyang, Henan Province, China
- 3 Department of Internal Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, United States, Sacramento, California, United States
The final, formatted version of the article will be published soon.
Corrigendum: The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer Chaokun Wang1, Shuzhen Deng2, Jing Chen1, Xiangyun Xu1, Xiaochen Hu1, Dejiu Kong1, Gaofeng Liang2, Xiang Yuan1, Yuanpei Li3*, Xinshuai Wang1* 1 Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China. 2 Medical College, Henan University of Science and Technology, Luoyang, China. 3 Department of Internal Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA * Correspondence: Xinshuai Wang; E-mail: xshuaiw@haust.edu.cn; Yuanpei Li; E-mail: lypli@ucdavis.edu Keywords: HER2 positive breast neoplasm; pyrotinib; adriamycin; synergistic; Akt Corrigendum on: full citation of the original version of the article. Error in Figure/Table In the published article, there was an error in Figure 3 as published. Due to the large number of photos taken, careless naming errors led to the accidental reuse of some images. The corrected Figure 3 and its caption **[ Figure 3. Effects of PYR and ADM on cell invasion.] appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: HER2 positive breast neoplasm, Pyrotinib, Adriamycin, Synergistic, Akt
Received: 28 Nov 2024; Accepted: 07 Feb 2025.
Copyright: © 2025 Wang, Deng, Chen, Xu, Hu, Kong, Liang, Yuan, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chaokun Wang, Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan Province, China
Shuzhen Deng, Medical College, Henan University of Science and Technology, Luoyang, 471003, Henan Province, China
Jing Chen, Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan Province, China
Xiangyun Xu, Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan Province, China
Xiaochen Hu, Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan Province, China
Dejiu Kong, Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan Province, China
Yuanpei Li, Department of Internal Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, United States, Sacramento, California, United States
Xinshuai Wang, Henan Key Laboratory of Cancer Epigenetics; Cancer hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.